NCT04609319 2025-05-31
Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review
Pfizer
Completed
Clinical Trials
19 trialsNCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT04511533 2024-04-05
Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations
Pfizer
Phase 4 Completed
NCT01774721 2023-11-14
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
Pfizer
Phase 3 Completed
NCT01000025 2023-08-22
PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT01920061 2022-09-13
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
Pfizer
Phase 1 Completed
NCT01520870 2021-07-06
Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.
Grupo Español de Investigación en Neurooncología
Phase 2 Completed
NCT00768664 2021-02-09
Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
Pfizer
Phase 2 Completed
NCT00553254 2020-10-19
Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer
Pfizer
Phase 2 Completed
NCT01918761 2019-12-30
Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
Central European Cooperative Oncology Group
Phase 1 Terminated
NCT00548093 2019-05-21
PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib
Pfizer
Phase 2 Completed
NCT01465802 2019-01-09
ARCHER 1042
Pfizer
Phase 2 Completed
NCT00818441 2019-01-08
Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung
Pfizer
Phase 2 Completed
NCT00728468 2017-08-02
A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients
Pfizer
Phase 1 Completed
NCT01858389 2017-07-18
A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 2 Completed
NCT01360554 2017-05-24
ARCHER 1009
Pfizer
Phase 3 Completed
NCT02047747 2016-09-22
A Phase II Study of Dacomitinib in Progressive Brain Metastases
University of California, San Diego
Phase 2 Terminated
NCT01121575 2015-10-28
A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer
Pfizer
Phase 1 Completed
NCT00769067 2015-10-07
A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen
Pfizer
Phase 2 Completed